Publicaciones en colaboración con investigadores/as de University of Cincinnati (29)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis

    Rheumatology (United Kingdom), Vol. 63, Núm. 9, pp. 2535-2546

  3. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  4. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

  5. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

  6. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

    European Journal of Cancer, Vol. 208

2023

  1. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

    International Journal of Gynecological Cancer, Vol. 33, Núm. 11, pp. 1733-1742

  2. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

  3. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570

  4. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

    Oral Oncology, Vol. 115

  3. The International Council of Ophthalmology Ophthalmic clinical evaluation exercise

    Indian Journal of Ophthalmology, Vol. 69, Núm. 1, pp. 43-47

2020

  1. Isn’t the evidence base for pediatric bipolar disorder already sufficient to inform clinical practice?

    Bipolar Disorders, Vol. 22, Núm. 7, pp. 664-665

  2. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1340-1348

2019

  1. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 71, Núm. 5, pp. 579-590

  2. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    Gynecologic Oncology

  3. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1094-1097

2018

  1. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

    Blood Advances, Vol. 2, Núm. 19, pp. 2491-2504

  2. Treatable inherited rare movement disorders

    Movement Disorders, Vol. 33, Núm. 1, pp. 21-35